Vasopressin as a target for antidepressant development: an assessment of the available evidence.

Hdl Handle:
http://hdl.handle.net/10147/209027
Title:
Vasopressin as a target for antidepressant development: an assessment of the available evidence.
Authors:
Scott, Lucinda V; Dinan, Timothy G
Affiliation:
Department of Psychiatry, Cork University Hospital, Cork, Ireland., lucinda@gofree.indigo.ie
Citation:
J Affect Disord. 2002 Nov;72(2):113-24.
Journal:
Journal of affective disorders
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/209027
PubMed ID:
12200202
Abstract:
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the key biological abnormalities described in major depressive disorder, occurring in 30-50% of depressed subjects. Corticotropin-releasing hormone (CRH) and vasopressin (AVP) are the main regulators of this stress system, with the two neuropeptides acting synergistically in bringing about adrenocorticotropin (ACTH) release from the anterior pituitary and cortisol from the adrenal gland. Based on the demonstration of elevated cerebrospinal fluid levels of CRH in depressives, and other evidence, it has been postulated that excess CRH and the resultant increased HPA forward drive form the basis of neuroendocrine dysregulation in depression. However, there is an accumulating body of evidence to support a significant role for AVP in the regulation of pituitary-adrenal activity in health and also in depressive disorder. This review, based on a Medline search from 1980 to 2001, focuses on the functional neuroanatomy, receptor pharmacology, VP synergism with CRH, and the data from clinical and pre-clinical studies that support an important role for AVP in the pathophysiology of major depression. We suggest that future antidepressants may target the vasopressinergic system.
Language:
eng
MeSH:
Adrenocorticotropic Hormone/cerebrospinal fluid/drug effects/metabolism; Antidepressive Agents/*pharmacology/*therapeutic use; Corticotropin-Releasing Hormone/cerebrospinal fluid/drug effects/metabolism; Depressive Disorder, Major/cerebrospinal fluid/*drug therapy/physiopathology; Fluoxetine/*pharmacology/*therapeutic use; Humans; Hydrocortisone/metabolism; Hypothalamo-Hypophyseal System/drug effects/metabolism/physiopathology; Pituitary-Adrenal System/drug effects/metabolism/physiopathology; Receptors, Vasopressin/drug effects; Vasopressins/cerebrospinal fluid/*drug effects/*metabolism
ISSN:
0165-0327 (Print); 0165-0327 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorScott, Lucinda Ven_GB
dc.contributor.authorDinan, Timothy Gen_GB
dc.date.accessioned2012-02-03T15:10:17Z-
dc.date.available2012-02-03T15:10:17Z-
dc.date.issued2012-02-03T15:10:17Z-
dc.identifier.citationJ Affect Disord. 2002 Nov;72(2):113-24.en_GB
dc.identifier.issn0165-0327 (Print)en_GB
dc.identifier.issn0165-0327 (Linking)en_GB
dc.identifier.pmid12200202en_GB
dc.identifier.urihttp://hdl.handle.net/10147/209027-
dc.description.abstractHyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the key biological abnormalities described in major depressive disorder, occurring in 30-50% of depressed subjects. Corticotropin-releasing hormone (CRH) and vasopressin (AVP) are the main regulators of this stress system, with the two neuropeptides acting synergistically in bringing about adrenocorticotropin (ACTH) release from the anterior pituitary and cortisol from the adrenal gland. Based on the demonstration of elevated cerebrospinal fluid levels of CRH in depressives, and other evidence, it has been postulated that excess CRH and the resultant increased HPA forward drive form the basis of neuroendocrine dysregulation in depression. However, there is an accumulating body of evidence to support a significant role for AVP in the regulation of pituitary-adrenal activity in health and also in depressive disorder. This review, based on a Medline search from 1980 to 2001, focuses on the functional neuroanatomy, receptor pharmacology, VP synergism with CRH, and the data from clinical and pre-clinical studies that support an important role for AVP in the pathophysiology of major depression. We suggest that future antidepressants may target the vasopressinergic system.en_GB
dc.language.isoengen_GB
dc.subject.meshAdrenocorticotropic Hormone/cerebrospinal fluid/drug effects/metabolismen_GB
dc.subject.meshAntidepressive Agents/*pharmacology/*therapeutic useen_GB
dc.subject.meshCorticotropin-Releasing Hormone/cerebrospinal fluid/drug effects/metabolismen_GB
dc.subject.meshDepressive Disorder, Major/cerebrospinal fluid/*drug therapy/physiopathologyen_GB
dc.subject.meshFluoxetine/*pharmacology/*therapeutic useen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHydrocortisone/metabolismen_GB
dc.subject.meshHypothalamo-Hypophyseal System/drug effects/metabolism/physiopathologyen_GB
dc.subject.meshPituitary-Adrenal System/drug effects/metabolism/physiopathologyen_GB
dc.subject.meshReceptors, Vasopressin/drug effectsen_GB
dc.subject.meshVasopressins/cerebrospinal fluid/*drug effects/*metabolismen_GB
dc.titleVasopressin as a target for antidepressant development: an assessment of the available evidence.en_GB
dc.contributor.departmentDepartment of Psychiatry, Cork University Hospital, Cork, Ireland., lucinda@gofree.indigo.ieen_GB
dc.identifier.journalJournal of affective disordersen_GB
dc.description.provinceMunster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.